174 related articles for article (PubMed ID: 14577491)
1. The expression of PAX5, p53 immunohistochemistry and p53 mutation analysis in superficial bladder carcinoma tissue. Correlation with pathological findings and clinical outcome.
Babjuk M; Soukup V; Mares J; Dusková J; Sedlácek Z; Trková M; Pecen L; Dvorácek J; Hanus T; Kocvara R; Novák J; Povýsil C
Int Urol Nephrol; 2002; 34(4):495-501. PubMed ID: 14577491
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C
Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
[TBL] [Abstract][Full Text] [Related]
3. Association of PAX5 expression with clinical outcome in patients with TaT1 transitional cell carcinoma of the bladder.
Babjuk M; Soukup V; Mares J; Dusková J; Pecen L; Pesl M; Pavlík I; DvorRcek J
Urology; 2006 Apr; 67(4):756-61. PubMed ID: 16566978
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.
Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J
Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850
[TBL] [Abstract][Full Text] [Related]
5. Detection of P53 tumor-suppressor-gene protein in bladder tumors and prostate cancer: possible clinical implications.
Kuczyk MA; Serth J; Hervatin C; Arndt H; Derendorf L; Thon WF; Jonas U
World J Urol; 1994; 12(6):345-51. PubMed ID: 7881474
[TBL] [Abstract][Full Text] [Related]
6. p53 Gene mutations in superficial bladder cancer.
Lorenzo Romero JG; Salinas Sánchez AS; Giménez Bachs JM; Sánchez Sánchez F; Escribano Martínez J; Hernández Millán IR; Segura Martín M; Virseda Rodríguez JA
Urol Int; 2004; 73(3):212-8. PubMed ID: 15539839
[TBL] [Abstract][Full Text] [Related]
7. MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1.
Olsson H; Hultman P; Rosell J; Söderkvist P; Jahnson S
BMC Urol; 2013 Jan; 13():5. PubMed ID: 23356517
[TBL] [Abstract][Full Text] [Related]
8. Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: a long-term study.
Salinas-Sánchez AS; Lorenzo-Romero JG; Giménez-Bachs JM; Sánchez-Sánchez F; Donate-Moreno MJ; Rubio-Del-Campo A; Hernández-Millán IR; Segura-Martín M; Atienzar-Tobarra M; Escribano-Martínez J
Urol Oncol; 2008; 26(6):620-6. PubMed ID: 18367096
[TBL] [Abstract][Full Text] [Related]
9. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
[TBL] [Abstract][Full Text] [Related]
10. Relationship between p53 gene mutation and protein expression: clinical significance in transitional cell carcinoma of the bladder.
Gao JP; Uchida T; Wang C; Jiang SX; Matsumoto K; Satoh T; Minei S; Soh S; Kameya T; Baba S
Int J Oncol; 2000 Mar; 16(3):469-75. PubMed ID: 10675477
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder.
Shiina H; Igawa M; Nagami H; Yagi H; Urakami S; Yoneda T; Shirakawa H; Ishibe T; Kawanishi M
Cancer; 1996 Oct; 78(8):1762-74. PubMed ID: 8859190
[TBL] [Abstract][Full Text] [Related]
12. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.
Esrig D; Spruck CH; Nichols PW; Chaiwun B; Steven K; Groshen S; Chen SC; Skinner DG; Jones PA; Cote RJ
Am J Pathol; 1993 Nov; 143(5):1389-97. PubMed ID: 7901994
[TBL] [Abstract][Full Text] [Related]
13. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Henke C; Korabiowska M; Schlott T; Zimmerman B; Kunze E
Anticancer Res; 2004; 24(2B):1011-23. PubMed ID: 15161057
[TBL] [Abstract][Full Text] [Related]
14. Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder.
Friedrich MG; Riethdorf S; Erbersdobler A; Tiemer C; Schwaibold H; Sölter JK; Huland E; Riethdorf L; Conrad S; Hammerer PG; Huland H
Eur Urol; 2001 Feb; 39(2):159-66. PubMed ID: 11223675
[TBL] [Abstract][Full Text] [Related]
15. The expression of PAX5 in human transitional cell carcinoma of the bladder: relationship with de-differentiation.
Adshead JM; Ogden CW; Penny MA; Stuart ET; Kessling AM
BJU Int; 1999 Jun; 83(9):1039-44. PubMed ID: 10368252
[TBL] [Abstract][Full Text] [Related]
16. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
Sarkis AS; Dalbagni G; Cordon-Cardo C; Zhang ZF; Sheinfeld J; Fair WR; Herr HW; Reuter VE
J Natl Cancer Inst; 1993 Jan; 85(1):53-9. PubMed ID: 7677935
[TBL] [Abstract][Full Text] [Related]
17. p53 expression predicts progression and poor survival in T1 bladder tumours.
Llopis J; Alcaraz A; Ribal MJ; Solé M; Ventura PJ; Barranco MA; Rodriguez A; Corral JM; Carretero P
Eur Urol; 2000 Jun; 37(6):644-53. PubMed ID: 10828662
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder.
Gontero P; Casetta G; Zitella A; Ballario R; Pacchioni D; Magnani C; Muir GH; Tizzani A
Eur Urol; 2000 Sep; 38(3):287-96. PubMed ID: 10940702
[TBL] [Abstract][Full Text] [Related]
19. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements.
Kunze E; Von Bonin F; Werner C; Wendt M; Schlott T
Int J Mol Med; 2006 Jan; 17(1):3-13. PubMed ID: 16328005
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
Dekairelle AF; Tombal B; Cosyns JP; Gala JL
Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]